Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7N4H9)

Drug Name
TAK-925 Drug Info
Synonyms
Danavorexton; TAK-925; 2114324-48-8; Danavorexton [INN]; 1QMD83K4YN; (2R,3S)-Methyl 3-(methylsulfonamido)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate; 1-Piperidinecarboxylic acid, 3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)-, methyl ester, (2R,3S)-; Methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate; methyl (2R,3S)-3-[(methanesulfonyl)amino]-2-({[(1s,4S)-4-phenylcyclohexyl]oxy}methyl)piperidine-1-carboxylate; A6F; UNII-1QMD83K4YN; TAK925; CHEMBL4650341; SCHEMBL19219900; GTPL11448; US10287305, Example 5; BDBM386067; BDBM386216; DTXSID401336757; GLXC-25309; EX-A6332; Example 5 [US10287305]; US10287305, Example 191; AKOS040757301; MS-27472; HY-133898; CS-0135024; EN300-2010728; methyl (2R,3S)-3- ((methylsulfonyl)amino)-2-(((cis-4- phenylcyclohexyl)oxy)methyl)- piperidine-1-carboxylate; methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate; methyl (2R,3S)-3-methanesulfonamido-2-({[(1s,4s)-4-phenylcyclohexyl]oxy}methyl)piperidine-1-carboxylate; methyl-d3 (2R,3S)-3- ((methylsulfonyl)amino)-2-(((cis-4- phenylcyclohexyl)oxy)methyl)- piperidine-1-carboxylate
Indication
Disease Entry ICD 11 Status REF
Narcolepsy 7A20 Phase 1 [1]
Cross-matching ID
PubChem CID
130310079
TTD Drug ID
DM7N4H9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Orexin receptor type 2 (HCRTR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Suvorexant DM0E6S3 Insomnia 7A00-7A0Z Approved [3]
MK-3697 DM347TQ Insomnia 7A00-7A0Z Phase 2 [4]
MIN-202 DMZFW8V Major depressive disorder 6A70.3 Phase 2 [5]
TAK-861 DMLGEQ7 Narcolepsy type 1 7A20.0 Phase 2 [6]
1,2-diamino cyclopentane-based derivative 25 DMEW0AT N. A. N. A. Patented [7]
1,2-diamino cyclopentane-based derivative 5 DMCP15K N. A. N. A. Patented [7]
1,2-diamino cyclopentane-based derivative 20 DM9PHIK N. A. N. A. Patented [7]
1,2-diamino cyclopentane-based derivative 15 DMBY65W N. A. N. A. Patented [7]
1,2-diamino cyclopentane-based derivative 13 DM10UX4 N. A. N. A. Patented [7]
1,2-diamino cyclopentane-based derivative 9 DM7I8ZV N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Orexin receptor type 2 (HCRTR2) TT9N02I OX2R_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT03748979) A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy. U.S.National Institutes of Health.
2 Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
7 Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.